Anticancer therapy

Norenberg, Jeffrey P.

Title: Anticancer therapy

Patent · Tue Apr 04 00:00:00 EDT 2017

OSTI ID:1349739

Norenberg, Jeffrey P.

A subject afflicted with a cancer or precancerous condition is treated by administering an agent that increases expression of somatostatin receptors, and a cytotoxic recognition ligand. In an alternative embodiment, somatostatin analogs, which are radiolabeled are used to treat cancer or precancerous conditions.

View Patent

Cite

Export

Save

Research Organization:: STC.UNM, Albuquerque, NM (United States)

Sponsoring Organization:: USDOE

DOE Contract Number:: FG01-001NE23554

Assignee:: STC.UNM

Patent Number(s):: 9,610,371

Application Number:: 14/669,313

OSTI ID:: 1349739

Resource Relation:: Patent File Date: 2015 Mar 26

Country of Publication:: United States

Language:: English

References (31)

Treatment of damaged bone marrow and dosage units therefor Borch, Richard F.; Schmalbach, Therese K. https://doi.org/https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/4938949 US Patent Document 4,938,949	patent	July 1990
Power-on reset circuit device for multi-level power supply sources Nagai, Nobutaka https://doi.org/https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5214316 US Patent Document 5,214,316	patent	May 1993
Complexes of functionalized tetraazacyclododecane chelates with bismuth, lead, ytriium, actinium, or lanthanide metal ions Gansow, Otto A.; Brechbiel, Martin W.; Magerstadt, Michael https://doi.org/https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5428154 US Patent Document 5,428,154	patent	June 1995
Multi-tyrosinated somatostatin analogs Coy, David H.; Woltering, Eugene A.; O'Dorisio, M. Sue https://doi.org/https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5597894 US Patent Document 5,597,894	patent	January 1997
Peptides Albert, Rainer; Macke, Helmut https://doi.org/https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5650134 US Patent Document 5,650,134	patent	July 1997
Cyclic peptide somatostatin analogs Dean, Richard T.; McBride, William; Lister-James, John https://doi.org/https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5932189 US Patent Document 5,932,189	patent	August 1999
Conformationally constrained backbone cyclized somatostatin analogs Hornik, Vered; Gellerman, Gary; Afargan, Mich El M. https://doi.org/https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6051554 US Patent Document 6,051,554	patent	April 2000
Highly sensitive multimeric nucleic acid probes Kool, Eric T. https://doi.org/https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6077668 US Patent Document 6,077,668	patent	June 2000
Somatostatin analogs for the treatment of cancer Burman, Anand C.; Prasad, Sudhanand; Mukherjee, Rama https://doi.org/https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6316414 US Patent Document 6,316,414	patent	November 2001
Somatostatin analogs Lister-James, John; Dean, Richard T.; Pearson, Daniel A. https://doi.org/https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6358491 US Patent Document 6,358,491	patent	March 2002
Conformationally constrained backbone cyclized somatostatin analogs Hornik, Vered; Afargan, Michel; Gellerman, Gary https://doi.org/https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6930088 US Patent Document 6,930,088	patent	August 2005
Peptide compounds having improved binding affinity to somatostatin receptors Macke, Helmut; Reubi, Jean Claude; Schmitt, Jörg https://doi.org/https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7122622 US Patent Document 7,122,622	patent	October 2006
RGD (Arg-Gly-Asp) coupled to (neuro)peptides DeJong, Marion; Krenning, Eric P.; Van Hagen, Petrus Martinus https://doi.org/https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7202330 US Patent Document 7,202,330	patent	April 2007
Nephrotoxicity in Mice After Repeated Imaging Using ¹¹¹In-Labeled Peptides Melis, M.; Vegt, E.; Konijnenberg, M. Journal of Nuclear Medicine, Vol. 51, Issue 6, p. 973-977 https://doi.org/10.2967/jnumed.109.074310	journal	May 2010
Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues Rolleman, Edgar; Melis, Marleen; Valkema, Roelf European Journal of Nuclear Medicine and Molecular Imaging, Vol. 37, Issue 5, p. 1018-1031 https://doi.org/10.1007/s00259-009-1282-y	journal	November 2009
Tumor Imaging and Therapy Using Radiolabeled Somatostatin Analogues de Jong, Marion; Breeman, Wout; Kwekkeboom, Dik Accounts of Chemical Research, Vol. 42, Issue 7, p. 873-880 https://doi.org/10.1021/ar800188e	journal	July 2009
Long-term toxicity of [¹⁷⁷Lu-DOTA⁰,Tyr³]octreotate in rats Rolleman, Edgar; Krenning, Eric; Bernard, Bert European Journal of Nuclear Medicine and Molecular Imaging, Vol. 34, Issue 2, p. 219-227 https://doi.org/10.1007/s00259-006-0232-1	journal	September 2006
Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings de Jong, Marion; Valkema, Roelf; Jamar, Francois Seminars in Nuclear Medicine, Vol. 32, Issue 2, p. 133-140 https://doi.org/10.1053/snuc.2002.31027	journal	April 2002
Phase I study of peptide receptor radionuclide therapy with [¹¹¹In-DTPA⁰]octreotide: The rotterdam experience Valkema, Roelf; de Jong, Marion; Bakker, Willem H. Seminars in Nuclear Medicine, Vol. 32, Issue 2, p. 110-122 https://doi.org/10.1053/snuc/2002.31025	journal	April 2002
Experimental facts supporting a red marrow uptake due to radiometal transchelation in ⁹⁰Y-DOTATOC therapy and relationship to the decrease of platelet counts Walrand, Stephan; Barone, Raffaella; Pauwels, Stanislas European Journal of Nuclear Medicine and Molecular Imaging, Vol. 38, Issue 7, p. 1270-1280 https://doi.org/10.1007/s00259-011-1744-x	journal	February 2011
Phase I Trial of ⁹⁰Y-DOTATOC Therapy in Children and Young Adults with Refractory Solid Tumors That Express Somatostatin Receptors Menda, Y.; O'Dorisio, M.; Kao, S. Journal of Nuclear Medicine, Vol. 51, Issue 10, p. 1524-1531 https://doi.org/10.2967/jnumed.110.075226	journal	September 2010
Lymphocytic Toxicity in Patients After Peptide-Receptor Radionuclide Therapy (PRRT) with ¹⁷⁷Lu-DOTATATE and ⁹⁰Y-DOTATOC Sierra, Maribel; Agazzi, Alberto; Bodei, Lisa Cancer Biotherapy & Radiopharmaceuticals, Vol. 24, Issue 6, p. 659-665 https://doi.org/10.1089/cbr.2009.0641	journal	December 2009
Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with ⁹⁰Y-DOTATOC and ¹⁷⁷Lu-DOTATATE: the role of associated risk factors Bodei, Lisa; Cremonesi, Marta; Ferrari, Mahila European Journal of Nuclear Medicine and Molecular Imaging, Vol. 35, Issue 10, p. 1847-1856 https://doi.org/10.1007/s00259-008-0778-1	journal	April 2008
Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide Barone, Raffaella; Walrand, Stéphan; Konijnenberg, Mark Nuclear Medicine Communications, Vol. 29, Issue 3, p. 283-290 https://doi.org/10.1097/MNM.0b013e3282f3d03e	journal	January 2008
Treatment with ⁹⁰Y- and ¹⁷⁷Lu-DOTATOC in patients with metastatic neuroendocrine tumors Frilling, Andrea; Weber, Frank; Saner, Fuat Surgery, Vol. 140, Issue 6, p. 968-977 https://doi.org/10.1016/j.surg.2006.07.030	journal	December 2006
Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial Pless, Miklos; Waldherr, Christian; Maecke, Helmut Lung Cancer, Vol. 45, Issue 3, p. 365-371 https://doi.org/10.1016/j.lungcan.2004.02.020	journal	September 2004
Receptor Radionuclide Therapy with ⁹⁰Y-DOTATOC in Patients with Medullary Thyroid Carcinomas Bodei, Lisa; Handkiewicz-Junak, Daria; Grana, Chiara Cancer Biotherapy & Radiopharmaceuticals, Vol. 19, Issue 1, p. 65-71 https://doi.org/10.1089/108497804773391694	journal	February 2004
Assessment of Hepatic Toxicity from Treatment with ⁹⁰Y-SMT 487 (OctreoTher™) in Patients with Diffuse Somatostatin Receptor Positive Liver Metastases Bushnell, David; Menda, Yusuf; Madsen, Mark Cancer Biotherapy & Radiopharmaceuticals, Vol. 18, Issue 4, p. 581-588 https://doi.org/10.1089/108497803322287664	journal	August 2003
⁹⁰Y-DOTA-D-Phe¹-Try³- octreotide in therapy of neuroendocrine malignancies Paganelli, G.; Bodei, L.; Handkiewicz Junak, D. Biopolymers, Vol. 66, Issue 6, p. 393-398 https://doi.org/10.1002/bip.10349	journal	January 2002
The clinical value of [⁹⁰Y-DOTA]-D-Phe¹-Tyr³-octreotide (⁹⁰Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study Waldherr, C.; Pless, M.; Maecke, H. Annals of Oncology, Vol. 12, Issue 7, p. 941-945 https://doi.org/10.1023/A:1011160913619	journal	July 2001
Yttrium-90 DOTATOC: first clinical results Otte, A.; Herrmann, R.; Heppeler, A. European Journal of Nuclear Medicine and Molecular Imaging, Vol. 26, Issue 11, p. 1439-1447 https://doi.org/10.1007/s002590050476	journal	October 1999

Similar Records

Anticancer therapy

Patent · Tue Jan 08 00:00:00 EST 2019 · OSTI ID:1349739

Norenberg, Jeffrey P.

Enhancement of Glioma Radiotherapy and Chemotherapy Response With Targeted Antibody Therapy Against Death Receptor 5

Journal Article · Sun Jun 01 00:00:00 EDT 2008 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:1349739

Gillespie, G Yancey; Oliver, Patsy G; Tong, Zhou; +2 more

Developmental change and molecular properties of somatostatin receptors in the rat cerebral cortex

Journal Article · Fri Apr 14 00:00:00 EDT 1989 · Biochem. Biophys. Res. Commun.; (United States) · OSTI ID:1349739

Kimura, N

Related Subjects

60 APPLIED LIFE SCIENCES
59 BASIC BIOLOGICAL SCIENCES

Title: Anticancer therapy

Citation Formats

References (31)

Similar Records

Related Subjects